News for POINT Biopharma Global Inc. (PNT)

Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 million for the four

Worldwide revenue of $378.7 million, an increase of 18.4% from third quarter 2023GAAP fully diluted earnings per share of $1.79, compared to $1.88 in the...

POINT Biopharma target raised to $105, maintains Hold rating

Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023Completed three strategic transactions to expand...

Eli Lilly continues to demonstrate promising long-term prospects. But read why it may be more prudent to maintain our previous Hold rating for LLY stock.

First Quarter 2024 Worldwide revenue of $370.0 million, an increase of 23.0% from first quarter 2023 GAAP fully diluted net income per share of $1.87,...

Strengths: Robust product pipeline and strong performance of key products.Weaknesses: High dependency on a few products and intense competition.Opportunities:

With an increasing emphasis on cutting-edge therapies and interventions to address the rising incidence of obesity globally, the global obesity market is a sizable industry.

An M&A deal between AstraZeneca (AZN) and Fusion Pharma (FUSN) reignites interest in a class of drugs known as radiopharmaceuticals. Read more here.

The international market for radiopharmaceuticals is projected to exceed $13.67B by 2032, with a compound annual growth rate of 10.2% from 2023. Read more here.

In this article, we will be taking a look at the 20 fastest growing biotech companies in the US.

NEW YORK, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential...

NEW YORK, Oct. 08, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential...

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.29%

U.S. stocks extended losses midway through trading, with the Nasdaq Composite falling more than 200 points on Tuesday. The Dow traded down 1.06% to 33,078.27 while the NASDAQ fell 1.60% to 13,094.83. The S&P 500 also fell, dropping, 1.27% to 4,233.76.

U.S. stocks traded lower this morning, with the Dow Jones falling more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.37% to 33,310.99 while the NASDAQ fell 0.58% to 13,230.96. The S&P 500 also fell, dropping, 0.47% to 4,268.18.

Read Investment Analysts’ Downgrades for May 31st (AAP, AEO, ANIOY, BKEAY, CECE, CLLNY, CQP, EPOKY, ESS, EXK) at ETF Daily News